Training and resources for safe research with dangerous pathogens
BSL-3 Practices Core
This study is all about helping researchers who work with dangerous germs, like the coronavirus, by giving them the training and tools they need to stay safe while they study these diseases, so they can find better ways to understand and treat infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10910192 on NIH RePORTER |
What this research studies
This research focuses on providing essential training and resources for researchers working with Biosafety Level 3 (BSL-3) pathogens, such as the novel coronavirus. It includes components like biosafety planning, user training, and oversight of compliance with safety regulations. The goal is to ensure that researchers are well-prepared to handle these pathogens safely and effectively, thereby supporting ongoing research efforts in infectious diseases. By enhancing safety protocols and training, the project aims to facilitate critical research that can lead to better understanding and management of infectious diseases.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include researchers and laboratory personnel who work with BSL-3 pathogens.
Not a fit: Patients who are not involved in research or laboratory work with infectious diseases may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could enhance the safety and effectiveness of research involving dangerous pathogens, ultimately contributing to better public health outcomes.
How similar studies have performed: Other research initiatives focusing on biosafety training and compliance have shown success in improving laboratory safety and research outcomes.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Adamovicz, Jeffrey Joseph — University of Missouri-Columbia
- Study coordinator: Adamovicz, Jeffrey Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.